Suppr超能文献

微小RNA-3133的表达与肾透明细胞癌患者的预后相关。

Expression of microRNA-3133 correlates with the prognosis in patients with clear cell renal cell carcinoma.

作者信息

Chen Xiaoyan

机构信息

Department of Urology, Zhongnan Hospital, Wuhan, Hubei, China.

出版信息

Medicine (Baltimore). 2019 Jun;98(24):e16008. doi: 10.1097/MD.0000000000016008.

Abstract

Clear cell renal cell carcinoma (ccRCC) represents a prevalent urological malignancy among men worldwide. MicroRNAs (miRNAs) are involved in the progression of diverse human cancers. The aim of this study was to explore the expression profile and prognostic value of microRNA-3133 (miR-3133) in ccRCC.The expression of miR-3133 in ccRCC tissues and non-cancerous tissues was measured by quantitative real-time polymerase chain reaction (qRT-PCR). Chi-square test was applied to evaluate the relationship between miR-3133 expression and clinical characteristics. Overall survival curve was constructed by Kaplan-Meier with log-rank test. The prognostic value of miR-3133 in ccRCC was estimated by Cox regression analysis.MiR-3133 was downregulated in ccRCC samples compared to the matched noncancerous samples (P <.01). Moreover, its expression level was correlated with T stage, vascular invasion and lymph node metastasis (all P <.05). Survival curves demonstrated that patients with low level of miR-3133 underwent lower overall survival than those with high level (log rank test, P = .002). MiR-3133 might be an independent prognostic biomarker in ccRCC patients (HR = 2.802, 95% CI = 1.391-5.646, P = .004).MiR-3133 is downregulated, and plays inhibitory roles in aggressive progression of ccRCC. MiR-3133 may be an independent prognostic biomarker for ccRCC.

摘要

透明细胞肾细胞癌(ccRCC)是全球男性中一种常见的泌尿系统恶性肿瘤。微小RNA(miRNA)参与多种人类癌症的进展。本研究旨在探讨微小RNA - 3133(miR - 3133)在ccRCC中的表达谱及预后价值。通过定量实时聚合酶链反应(qRT - PCR)检测ccRCC组织和癌旁组织中miR - 3133的表达。应用卡方检验评估miR - 3133表达与临床特征之间的关系。采用Kaplan - Meier法构建总生存曲线并进行对数秩检验。通过Cox回归分析评估miR - 3133在ccRCC中的预后价值。与匹配的癌旁样本相比,ccRCC样本中miR - 3133表达下调(P <.01)。此外,其表达水平与T分期、血管侵犯和淋巴结转移相关(均P <.05)。生存曲线显示,miR - 3133低水平患者的总生存率低于高水平患者(对数秩检验,P = .002)。miR - 3133可能是ccRCC患者的独立预后生物标志物(HR = 2.802,95%CI = 1.391 - 5.646,P = .004)。miR - 3133表达下调,在ccRCC的侵袭性进展中起抑制作用。miR - 3133可能是ccRCC的独立预后生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/6587602/005e43b0df25/medi-98-e16008-g002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验